# US 2020/0368313 A1 · Drug delivery systems for treatment of infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368313 A1
- Document ID: US20200368313A1
- Status: Published application
- Kind: A1
- Application number: 16/958,647
- Filed: 2018-12-28
- Published: 2020-11-26
- Earliest claimed: 2017-12-29
- Assignees: Wayne State University
- Applicants: Wayne State University
- Inventors: Arun K. Iyer; Samaresh Sau; Michael Rybak; Ketki Bhise; Razie Kebriaei
- Web page: https://patentgrep.com/patent/US20200368313A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/6911: {the form being a liposome}
- A61L 15/44: Medicaments
- A61L 15/46: Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- A61L 2300/406: Antibiotics
- A61L 2300/626: Liposomes, micelles, vesicles
- A61L 2300/64: Animal cells
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the FIG. 5 treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

## Claims

### Claim 1

A method of treating Staphylococcus (S.) aureus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liposomal nanoparticle comprising:
a lipid component comprising a 1:0.5:0.07 ratio of HSPC to cholesterol to DSPE-mPEG, or a 1:0.05:0.007:0.007 ratio of HSPC to cholesterol to DSPE-mPEG to DSPE-PEG-Folate; or a 1:0.5:0.07 ratio of DOTAP to cholesterol to DSPE-mPEG;
at least 10% vancomycin; and
cefazolin, thereby treating S. aureus infection in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the liposomal nanoparticle was made using a modified water in oil (reverse phase) evaporation method described herein.

### Claim 3

A method of treating Staphylococcus (S.) aureus infection in a subject in need thereof, comprising administering a therapeutically effective amount of a drug delivery system comprising vancomycin and cefazolin to the subject thereby treating S. aureus infection in the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the S. aureus infection is a Methicillin-Resistant Staphylococcus aureus (MRSA) infection or a Methicillin-Susceptible S. aureus (MSSA) infection.

### Claim 5 (depends on 3)

The method of claim 3 wherein the drug delivery system comprises a liposomal nanoparticle comprising:
a lipid component comprising HSPC, Cholesterol, and DSPE-mPEG; and
vancomycin, cefazolin, or a mixture thereof.

### Claim 6 (depends on 3)

The method of claim 3, wherein drug delivery system comprises one or more of a nanoparticle, a macroparticle, an emulsion, an organogel, a nanogel, an ointment, a cream, a liposome, a multivesicular liposome (MLV), a microsphere, a nanosphere, and/or a detergent.

### Claim 7 (depends on 3)

The method of claim 3, wherein drug delivery system comprises a lipid component comprising one or more of natural and synthetic phospholipid, sphingolipid, fatty acid modified lipid, cationic lipid, pH sensitive lipid, anionic lipid, neutral lipid, zwitterionic lipid, antigenic lipid, alkyl phosphate lipid, chelator functionalized lipid, glycosylated lipid, antigenic lipid, adhesive lipid, polymerizable lipid, crosslinking lipid, pegylated lipid, functionalized peg lipid, and/or a chemical conjugation to the vancomycin and/or cefazolin.

### Claim 8 (depends on 7)

The method of claim 7, wherein the drug delivery system comprises:
one or more of natural or synthetic egg sphingosine, brain sphingosine, sphingosine (d14:1), sphingosine (d16:1), sphingosine (d17:1), sphingosine (d18:1), sphingosine (d20:1), sphingosine 4E,8Z, sphingosine 4E,11Z, 4E,14Z-Sphingadiene, Safingol, sphinganine-1-phosphate (d17:0), (d18:0), (d20:0), (d17:1), (d18:1), (d20:1), methylated sphingosine, phytosphingosine, phosphosphingolipid lipid, and/or glycosphingolipids; and/or
one or more of (2S—OH) or (2R—OH) of 12:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0, 18:1, or 24:1 Ceramide; or phytoceramide; and/or
a cationic lipid comprising one or more of N1[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino] butylcarboxamido) ethyl]-3,4-di[oleyloxy]-benzamide; 1,2-di-O-octadecenyl-3-trimethylammonium propane; (14:0), (14:1), (16:0), (16:1), (18:0), (18:1), (12:0) 1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine; (18:1), (18:0), (16:0), (16:1), (14:0) 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP/TAP); 3β-[N-(N′, N′-dimethylaminoethane)-carbamoyl]cholesterol; and/or N4-Cholesteryl-Spermine; and/or
a pH sensitive lipid comprising one or more of 1,2-dioleoyl-3-dimethylammonium-propane; 1,2-dimyristoyl-3-dimethylammonium-propane; 1,2-dipalmitoyl-3-dimethylammonium-propane; 1, 2-distearoyl-3-dimethylam monium-propane; or N-(4-carboxybenzyl)-N, N-dimethyl-2 , 3-bis(oleoyloxy)propan-1-aminium; and/or
an anionic lipid comprising one or more of cholesteryl, hemisuccinate; or Dicetyl phosphate; and/or
a neutral lipid comprising one or more of 1,2-dioctadecanoyl-sn-glycerol; 1-octadecanoyl-2-hexadecanoyl-sn-glycerol; 16:0 ethylene glycol; 1-stearoyl-2-linoleoyl-sn-glycerol; diacyl glycerols; or glycosylated diacyl glycerols; and/or
a zwitterionic lipid comprising one or more of 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate; 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate; N,N-dimethyldodecylamine N-oxide, DOPC, POPC, DLPC, HSPC, DOPE, HSPC, or L-β-hydrogenated phosphatidylcholine; and/or
an antigenic lipid comprising one or more of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(2,4-dinitrophenyl); 1,2-dipalmitoyl-sn-glycero-3-phosphoethanol-amine-N-[6-[(2,4-dinitrophenyl) amino]hexanoyl; or 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-(2,4,6-trinitrophenyl); and/or
a polymeric, crosslinking lipid or polymerizable lipid comprising one or more of 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine; Chol-PEG(500-5000), DSPE-PEG(500-5000)-0M E, DSPE-PEG(500-5000)-SH, DSPE-PEG(500-5000)-NH2, DSPE-PEG(500-5000)-Maliamide, DSPE-PEG(500-5000)-DBCO, DSPE-PEG(500-5000)- Biotin, DSPE-PEG(500-5000)- Azide, DSPE-PEG(500-5000)-carboxylic acid, DSPE-PEG(500-5000)-Succinyl, DSPE-PEG (500-5000)-folate; 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine; or C16 PEG750 Ceramide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the drug delivery system comprises a leucocyte, fibroblast, neutrophil, or lymphocyte targeting ligand, or a targeting ligand specific to a bacterial cell or the cell of a host cell associated with a bacterial cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein the targeting ligand is a folate receptor beta (FRa,β), a toll-like receptor (TLR), a hyaluronan receptor (CD44), a T cell receptor (TCR) of immune cells, a protein A receptor on the surface of S. aureus, or an the extracellular protein expressed by leukocytes.

### Claim 11 (depends on 9)

The method of claim 9, wherein the drug delivery system comprises one or more of folic acid, methotrexate, aminopterin, antibody, peptides for targeting FR; lipopeptides, lipoprotein, small oligonucleotide sequences for targeting TLR; hyaluronic acid (HA) for targeting CD44; linagliptin, and other xanthine scaffold for targeting fibroblast activation protein (FAP) of wound fibroblast cells;

### Claim 12 (depends on 9)

The method of claim 9, wherein the leucocyte targeting ligand is folic acid or another folate receptor ligand.

### Claim 13 (depends on 1)

The method of claim 1, wherein the drug delivery system comprises a carbonic anhydrase (CA) targeting ligand.

### Claim 14 (depends on 13)

The method of claim 13, wherein the CA targeting ligand comprises imidazole, sulfoimidazole derivative, acetazolamide; methazolamide; ethoxzolamide; dichorophenamide; dorzolamide; brinzolamide; benzolamide; topiramate; zonisamide; sulpiride; indisulam; celecoxib; valdecoxib; antibody, or a peptide.

### Claim 15 (depends on 13)

The method of claim 13, wherein the CA targeting ligand is acetazolamide.

### Claim 16 (depends on 9)

The method of claim 9, wherein the targeting ligand, the vancomycin, and/or the cefazolin is chemically conjugated with lipid molecule(s) of the liposomes.

### Claim 17 (depends on 1)

The method of claim 1, wherein the treatment is a therapeutic or a prophylactic treatment.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administering comprises injection, oral administration, or topical administration.

### Claim 19 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises a 1:10 ratio of vancomycin to lipid.

### Claim 20 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises a 1:1 ratio of cefazolin to lipid.

### Claim 21 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises a 1:0.5:0.07 ratio of HSPC to cholesterol to DSPE- mPEG.

### Claim 22 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises a 1:0.05:0.007:0.007 ratio of HSPC to cholesterol to DSPE- mPEG to DSPE-PEG-Folate.

### Claim 23 (depends on 6)

The method of claim 6, wherein the nanoparticle is within a population of nanoparticles having a mean diameter of 192.9 nm, or having a mean diameter of 176.5 nm.

### Claim 24 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises at least 10% vancomycin.

### Claim 25 (depends on 24)

The method of claim 24, wherein the nanoparticle comprises at least 30% vancomycin.

### Claim 26

A method of reducing the nephrotoxicity associated with therapeutic vancomycin administration to a subject, the method comprising administering a preparation comprising a therapeutically effective amount of a lipid nanoparticle comprising vancomycin and cefazolin to the subject thereby reducing the nephrotoxicity associated with therapeutic vancomycin administration in the subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein the therapeutic vancomycin administration provides one or more of:
a therapeutic treatment in the subject;
a prophylactic treatment in the subject;
an anti-infection effect against a Methicillin-Resistant Staphylococcus aureus (MRSA) infection; and/or
an anti-infection effect against a Methicillin-Susceptible S. aureus (MSSA) infection.

### Claim 28 (depends on 26)

The method of claim 26, wherein the lipid nanoparticle comprises a leucocyte targeting ligands.

### Claim 29 (depends on 28)

The method of claim 28, wherein the leucocyte targeting ligand is folic acid.

### Claim 30 (depends on 26)

The method of claim 26, wherein the lipid nanoparticle comprises a carbonic anhydrase (CA) targeting ligand.

### Claim 31 (depends on 30)

The method of claim 30, wherein the CA targeting ligand is acetazolamide.

### Claim 32 (depends on 26)

The method of claim 26, wherein the administering is by injection, oral administration, or topical administration.

### Claim 33 (depends on 26)

The method of claim 26, wherein the nanoparticle comprises a 1:10 ratio of vancomycin to lipid.

### Claim 34 (depends on 26)

The method of claim 26, wherein the nanoparticles comprises a 1:1 ratio of cefazolin to lipid.

### Claim 35 (depends on 26)

The method of claim 26, wherein the nanoparticle comprises a 1:5:0.07 ratio of HSPC to cholesterol to DSPE- mPEG.

### Claim 36 (depends on 26)

The method of claim 26, wherein the nanoparticle comprises a 1:0.05:0.007:0.007 ratio of HSPC to cholesterol to DSPE- mPEG to DSPE-PEG-Folate.

### Claim 37 (depends on 26)

The method of claim 26, wherein the nanoparticle is within a population of nanoparticles having a mean diameter of 192.9 nm.

### Claim 38 (depends on 26)

The method of claim 26, wherein the nanoparticle is within a population of nanoparticles having a mean diameter of 176.5 nm.

### Claim 39

A lipid nanoparticle or drug delivery system comprising at least 10% vancomycin.

### Claim 40 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising cefazolin.

### Claim 41 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising leucocyte targeting ligands.

### Claim 42 (depends on 41)

The lipid nanoparticle or drug delivery system of claim 41 wherein the leucocyte targeting ligand is folic acid.

### Claim 43 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising a carbonic anhydrase (CA) targeting ligand.

### Claim 44 (depends on 43)

The lipid nanoparticle or drug delivery system of claim 43 comprising wherein the CA targeting ligand is Acetazolamide.

### Claim 45 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 formulated for injection, for topical administration, for oral administration, or for use within a transdermal patch or wound dressing.

### Claim 46 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising a 1:10 ratio of vancomycin to lipid.

### Claim 47 (depends on 40)

The lipid nanoparticle or drug delivery system of claim 40 comprising a 1:1 ratio of cefazolin to lipid.

### Claim 48 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising a 1:0.5:0.07 ratio of HSPC to cholesterol to DSPE-mPEG.

### Claim 49 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising a 1:0.05:0.007:0.007 ratio of HSPC to cholesterol to DSPE- mPEG to DSPE-PEG-Folate.

### Claim 50 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 within a population of nanoparticles having a mean diameter of 192.9 nm.

### Claim 51 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 within a population of nanoparticles having a mean diameter of 176.5 nm.

### Claim 52 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39, wherein the nanoparticle comprises at least 30% vancomycin.

### Claim 53

A modified water in oil (reverse phase) evaporation method for making a liposome nanoparticle with high vancomycin loading, the method comprising:
dissolving in a 1:1 mixture of diethyl ether: chloroform:
HSPC: cholesterol: DSPE-mPEG in a 1:0.5:0.07 ratio (w/w), or
HSPC: cholesterol: DSPE-mPEG: DSPE-PEG-Folate in a 1:0.05:0.007:0.007 ratio (w/w), or
DOTAP: cholesterol: DSPE-mPEG in a 1:0.5:0.07 ratio (w/w);
evaporating the organic phase to obtain a thin film of lipid mixture;
re-dissolving the resulting thin film in the same organic phase at the same ratio and adding an equal volume of sterile PBS to form an emulsion;
breaking the emulsion by high energy cavitation produced using a sonicator;
evaporating the organic phase to obtain a clear liposomal solution;
separating unencapsulated vancomycin from the clear liposomal solution by gel column filtration; and
size-extruding at 60° C. through 200 nm and 100 nm membranes.

### Claim 54 (depends on 53)

The method of claim 53, further comprising subjecting the clear liposomal solution to multiple freeze-thaw cycles.

### Claim 55

A method of forming a nanoparticle disclosed herein utilizing water in oil emulsion, reverse phase evaporation.

### Claim 56 (depends on 55)

The method of claim 55, wherein the nanoparticle encapsulates vancomycin, cefazolin, or a mixture of vancomycin and cefazolin.

### Claim 57 (depends on 53, 54, 55, 56)

A nanoparticle prepared using the method of any one of claims 53-56.

### Claim 58 (depends on 57)

The nanoparticle of claim 57, comprising at least 10% (w/w) vancomycin, at least 10% (w/w) cefazolin, or at least 10% (w/w) of a mixture of vancomycin and cefazolin.

### Claim 59 (depends on 6)

The method of claim 6, wherein the nanoparticle comprises a 1:0.5:0.07 ratio of DOTAP to cholesterol to DSPE-m PEG.

### Claim 60 (depends on 26)

The method of claim 26, wherein the nanoparticle comprises a 1:0.5:0.07 ratio of DOTAP to cholesterol to DSPE-m PEG.

### Claim 61 (depends on 39)

The lipid nanoparticle or drug delivery system of claim 39 comprising a 1:0.5:0.07 ratio of DOTAP to cholesterol to DSPE-mPEG.

### Claim 62

Use of an antibiotic chemically conjugated with a lipid molecule as an active component of a therapeutic liposome, to improve the stability and long circulation of the antibiotic, substantially as described herein.

### Claim 63

Liposomes in the hydrophilic core of which are captured one or more oligomicelles (OMs) comprising at least one conjugated or encapsulated antibiotic, substantially as described herein.
